ABL Diagnostics (Paris:ABLD)(Euronext Compartment B – ISIN: FR001400AHX6), a company specialized in in vitro diagnostics, today announces its annual results for the fiscal year ended December 31, 2025 ...
ABL Diagnostics (Paris:ABLD) announces that it has made its 2025 Annual Financial Report available to the public and filed it with the Autorité des marchés financiers (AMF).
14d
Arch Capital Management Launches to Provide Flexible Working Capital, Factoring, and ABL Facilities
Arch Capital Management (“Arch”), a new working capital and asset-based lending platform, today announced its official launch, expanding the team’s commitment to helping growth-oriented businesses ...
Insights from the Secured Finance Network show steady ABL activity and strong factoring growth despite a moderating economic environment and a flurry of private credit headlines NEW YORK--(BUSINESS ...
Hosted on MSN
Acuity trims ABL outlook but keeps AIS growth target
Sales outlook shift: Management now expects ABL sales to be flat to down low single digits for the year, citing slower project releases and macro uncertainty. AIS growth steady: AIS segment continues ...
ABL Group has signed a one-year master service agreement with offshore vessel operator Tidewater to provide marine assurance and dynamic positioning consultancy services. The agreement, entered into ...
1mon
ABL Bio Inc.
ABL Bio Inc. research and ratings by Barron's. View 298380 revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results